Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 20...
October 17 2016 - 7:30AM
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing
company, today announced that its scientists will present data on
the use of CRISPR/Cas9-mediated gene editing in human hematopoietic
stem/progenitor cells in a poster presentation at the 24th Annual
Congress of the European Society of Gene and Cell Therapy, hosted
in conjunction with the 2016 International Symposia of the
International Society for Stem Cell Research. The meeting will take
place Oct. 18-21 at the Palazzo dei Congressi in Florence, Italy.
The following is a short summary and timing for the poster
presentation:
Title: Highly efficient CRISPR/Cas9 mediated
gene editing in long-term engrafting human hematopoietic
stem/progenitor cells
Authors: J. M. Heath, A. Chalishazar, C.S. Lee,
W. Selleck, C. Cotta-Ramusino, D. Bumcrot, J.L. Gori
Date/Time: 6:30-8:30 p.m. CEST, Wednesday, Oct.
19
About Editas MedicineEditas Medicine is a
leading genome editing company dedicated to treating patients with
genetically defined diseases by correcting their disease-causing
genes. The company was founded by world leaders in genome editing,
and its mission is to translate the promise of genome editing
science into a broad class of transformative genomic medicines to
benefit the greatest number of patients.
Forward Looking StatementsThis press release
contains forward-looking statements and information within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’
‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. The Company may
not actually achieve the plans, intentions, or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements.
Actual results or events could differ materially from the
plans, intentions and expectations disclosed in these
forward-looking statements as a result of various factors,
including: uncertainties inherent in the initiation and completion
of preclinical studies and clinical trials and clinical development
of the Company’s product candidates; availability and timing of
results from preclinical studies and clinical trials; whether
interim results from a clinical trial will be predictive of the
final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products and availability of funding sufficient for the
Company’s foreseeable and unforeseeable operating expenses and
capital expenditure requirements. These and other risks are
described in greater detail under the caption “Risk Factors”
included in the Company’s most recent Quarterly Report on Form
10-Q, which is on file with the Securities and Exchange
Commission, and in other filings that the Company may make with
the Securities and Exchange Commission in the
future. Any forward-looking statements contained in this
press release speak only as of the date hereof, and the Company
expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Media Contact
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor Contact
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2023 to Apr 2024